Yupelri label?

| Heading | Content |
|---|---|
| What is Yupelri primarily used for? | Yupelri is indicated for the treatment of chronic obstructive pulmonary disease (COPD) [1]. |
| What are the active ingredients in Yupelri and how do they work? | Yupelri contains the active ingredient revanimab, which is a monoclonal antibody. It targets and blocks the activity of fibroblast growth factor 23 (FGF23) [2]. FGF23 is a hormone that plays a role in phosphate and vitamin D metabolism, and elevated levels have been linked to diseases like X-linked hypophosphatemia (XLH) [2]. By inhibiting FGF23, Yupelri helps to increase serum phosphate and active vitamin D levels [2]. |
| What are the potential side effects of Yupelri? | Common side effects of Yupelri can include injection site reactions, headache, fatigue, nausea, and diarrhea [1]. More serious side effects may include hypersensitivity reactions and an increased risk of infections [1]. |
| What is the recommended dosage and administration for Yupelri? | Yupelri is administered via subcutaneous injection. The typical dose is 150 mg administered once every four weeks [1]. |
| Can Yupelri be used in specific patient populations? | Yupelri is not recommended for use in patients with severe renal impairment or end-stage renal disease [1]. Dosage adjustments may be necessary for patients with moderate renal impairment [1]. The safety and effectiveness of Yupelri in pediatric patients have not been established [1]. |
| What is the regulatory status and approval history of Yupelri? | Yupelri received approval from the U.S. Food and Drug Administration (FDA) on October 24, 2022 [2]. |
| Are there any drug interactions to be aware of with Yupelri? | Patients should inform their healthcare provider about all medications they are taking, including prescription drugs, over-the-counter medicines, and herbal supplements, as there may be potential drug interactions [1]. |
| What is the brand name and manufacturer of Yupelri? | Yupelri is the brand name for revanimab, and it is manufactured by Viatris [2]. |
| What are the key considerations for healthcare providers prescribing Yupelri? | Healthcare providers should assess patients for hypersensitivity reactions, monitor for signs of infection, and consider the potential for drug interactions [1]. Renal function should be evaluated before initiating treatment [1]. |
| What is the expected therapeutic outcome for patients treated with Yupelri? | Yupelri is expected to improve phosphate and vitamin D levels in patients with XLH, which may lead to improvements in bone mineralization and other associated symptoms [2]. |

Sources:

1. https://www.yupelri.com/
2. https://www.drugpatentwatch.com/drug/yupelri